Janssen’s Amivantamab Combo Shows Promise In First-Line NSCLC
Tagrisso Head-To-Head Set To Begin
Janssen presents highly encouraging interim results at ESMO from the CHRYSALIS study with a combination of amivantamab and lazertinib. Based on the data, the global Phase III MARIPOSA study, which will assess the combo versus blockbuster Tagrisso, will begin next month including in South Korea, home to lazertinib's originator.
